UNSPSC 51384903: Ruvazone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C12H14N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O5U67O8927, chemically known as pyruvic acid, o-ethoxybenzoylhydrazone but generally known as ruvazone, which bears US NIH Compound Identifier 9570360. European Medicines Agency schedules Ruvazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10408MIG.

UNSPSC 51384903 Ruvazone is a Commodity code under which state and local governments procure naloxone and drug deactivation systems for community health and emergency response initiatives. Recent solicitations show government agencies buying naloxone units and Safe Drug Deactivation Systems through competitive bidding processes, with orders ranging from hundreds to thousands of units annually. State and local issuing bodies pursuing this code include county health departments and state health and human services commissions, along with multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. Procurement typically flows through traditional competitive processes—IFBs and RFPs—with vendors expected to handle delivery, maintain compliance certifications including E-Verify and drug-free workplace attestation, and carry specified insurance including commercial general liability and professional liability coverage.

Geographic activity centers on Florida and Minnesota, with recent solicitations posted from Seminole County, Florida (IFB60459723LAS, response deadline July 26, 2023, seeking 1,900 units of naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries) and the Minnesota Multistate Cooperative Purchasing Alliance covering Oregon and participating states (RFP S1070000015802, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products through authorized wholesalers). Texas HHS Commission issued a Request for Information in April 2026 exploring direct-to-manufacturer prescription programs, though that solicitation diverges from the naloxone-specific scope of the code. The Seminole County IFB represents the most directly aligned recent opportunity under this code, with fixed-fee pricing and a two-year initial term plus one-year renewal option. No explicit set-aside designations or disadvantaged-enterprise restrictions appear in the recent postings.